References
- Vinar D., Grof P. Proheptatriene in depression (extensive study). Activ. Nerv. Suppl. 1965; 7: 290–301
- Benesova O., Nahunek K. Correlation between the experimental data from animal studies and therapeutical effects of antidepressant drugs. Psyehopharmacologia 1971; 20: 337–347
- Lance J. W., Anthony M. Cyclobenzaprine in the treatment of chronic tension headache. Med. J. Aust. 1972; 2: 1409–1411
- Tourtellotte W. W., Potvin A. R., Constanza A. M., Hirsh S. B., Syndulko K. Cyclobenzaprine A new type of anti-Parkinsonian drug. Prog. Neur-Psychopharmacol. 1978; 2: 553–578
- Share N. N., McFarlane C. S. Cyclobenzaprine: A novel centrally acting skeletal muscle relaxant. Neuropharmacol. 1975; 12: 675–684
- Jones R. F., Burke D., Morosszeky J. E., Gillies J. D. A new agent for the control of spasticity. J. Neurol. Neurosurg Psychiat. 1970; 33: 464–468
- Ashby P., Burke D., Rao S., Jones R. F. Assessment of cyelobenzaprine in the treatment of spasticity. J. Neurol. Neurosurg. Psychiat. 1972; 35: 599–605
- Flexeril(R) Prescribing information. Merck, Sharp and Dohme, West Point, PA. 1981
- Hughes M. J., Lemons S., Barnes C. Cyelobenzaprine: Some pharmacological cardiac actions. Life Sci. 1978; 23: 2779–2786
- Nibbelink D. W., Strickland S. C. Cyelobenzaprine (FlexerilW) postmarketing surveillance program: preliminary report. Cur. Ther. Res. 1979; 25: 564–570
- Nibbelink D. W., Strickland S. C. Cyelobenzaprine (FlexerilW): Report of a post-marketing surveillance program. Cur. Ther. Res. 1980; 28: 894–903
- Biggs J. T., Spiker D., Petit J. M., Ziegler V. E. Tricyclic antidepressant overdose: Incidence of symptoms. JAMA 1977; 238: 135–138
- Rumack B. H. Anticholinergic poisoning: Treatment with physostigmine. Pediatrics 1973; 52: 449–451
- Heiser J. F., Gillan J. C. The reversal of anticholinergic drug-induced delirium and coma with physostigmine. Am. J. Psychiat. 1971; 127: 1051–1054
- Newton R. W. Physostigmine salicylate in the treatment of tricyclic antidepressant overdosage. JAMA 1975; 231: 941–943
- Hucker H. B., Stauffer S. C., Albert K. S., Lei B. W. Plasma levels and bioavailability of cyelobenzaprine in human subjects. J. Clin. Pharmacol. 1977; 17: 719–727
- Sharre N. N. Pharmacological properties of cyelobenzaprine. In clinical evaluation of FlexerilW, postgraduate medicine communication. McGraw-Hill. 1978